Literature DB >> 32022242

Growth pattern of experimental glioblastoma.

Jonatan Ahlstedt1, Karolina Förnvik1, Gunther Helms2, Leif G Salford1, Crister Ceberg2, Gunnar Skagerberg3, Henrietta Nittby Redebrandt3,4.   

Abstract

Glioblastoma multiforme (GBM) is an aggressive primary brain malignancy with a very poor prognosis. Researchers employ animal models to develop potential therapies. It is important that these models have clinical relevance. This means that old models, propagated for decades in cultures, should be questioned. Parameters to be evaluated include whether animals are immune competent or not, the infiltrative growth pattern of the tumor, tumor volume resulting in symptoms and growth rate. We here describe the growth pattern of an experimental glioblastoma model in detail with GFP positive glioblastoma cells in fully immune competent animals and study tumor growth rate and tumor mass as a function of time from inoculation. We were able to correlate findings made with classical immunohistochemistry and MR findings. The tumor growth rate was fitted by a Gompertz function. The model predicted the time until onset of symptoms for 5000 inoculated cells to 18.7±0.4 days, and the tumor mass at days 10 and 14, which are commonly used as the start of treatment in therapeutic studies, were 5.97±0.62 mg and 29.1±3.0 mg, respectively. We want to raise the question regarding the clinical relevance of the outline of glioblastoma experiments, where treatment is often initiated at a very early stage. The approach presented here could potentially be modified to gain information also from other tumor models.

Entities:  

Mesh:

Year:  2020        PMID: 32022242     DOI: 10.14670/HH-18-207

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  26 in total

Review 1.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 2.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

3.  Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model.

Authors:  Berwini B Endaya; Paula Y P Lam; Adrian C B Meedeniya; Jiri Neuzil
Journal:  Mol Oncol       Date:  2015-09-10       Impact factor: 6.603

4.  Structural and quantitative neuroimaging of the common marmoset monkey using a clinical MRI system.

Authors:  Gunther Helms; Enrique Garea-Rodriguez; Christina Schlumbohm; Jessica König; Peter Dechent; Eberhard Fuchs; Melanie Wilke
Journal:  J Neurosci Methods       Date:  2013-03-06       Impact factor: 2.390

Review 5.  High-grade glioma mouse models and their applicability for preclinical testing.

Authors:  Nienke A de Vries; Jos H Beijnen; Olaf van Tellingen
Journal:  Cancer Treat Rev       Date:  2009-09-19       Impact factor: 12.111

Review 6.  Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.

Authors:  Antonin Dréan; Lauriane Goldwirt; Maïté Verreault; Michael Canney; Charlotte Schmitt; Jeremy Guehennec; Jean-Yves Delattre; Alexandre Carpentier; Ahmed Idbaih
Journal:  Expert Rev Neurother       Date:  2016-07-04       Impact factor: 4.618

7.  NIK regulates MT1-MMP activity and promotes glioma cell invasion independently of the canonical NF-κB pathway.

Authors:  C L Duran; D W Lee; J-U Jung; S Ravi; C B Pogue; L G Toussaint; K J Bayless; R Sitcheran
Journal:  Oncogenesis       Date:  2016-06-06       Impact factor: 7.485

8.  Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1.

Authors:  Jonatan Ahlstedt; Karolina Förnvik; Shaian Zolfaghari; Dongoh Kwak; Lars G J Hammarström; Patrik Ernfors; Leif G Salford; Henrietta Nittby Redebrandt
Journal:  Oncotarget       Date:  2018-01-03

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

10.  C1-inactivator is upregulated in glioblastoma.

Authors:  Karolina Förnvik; Aida Maddahi; Oscar Persson; Kurt Osther; Leif G Salford; Henrietta Nittby Redebrandt
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

View more
  2 in total

1.  Comparable Long-Term Tumor Control for Hypofractionated FLASH Versus Conventional Radiation Therapy in an Immunocompetent Rat Glioma Model.

Authors:  Elise Konradsson; Emma Liljedahl; Emma Gustafsson; Gabriel Adrian; Sarah Beyer; Suhayb Ehsaan Ilaahi; Kristoffer Petersson; Crister Ceberg; Henrietta Nittby Redebrandt
Journal:  Adv Radiat Oncol       Date:  2022-07-02

2.  Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma.

Authors:  Emma Liljedahl; Elise Konradsson; Emma Gustafsson; Karolina Förnvik Jonsson; Jill K Olofsson; Crister Ceberg; Henrietta Nittby Redebrandt
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.